Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2013

01-12-2013 | Research Article

Associations between vitamin D receptor polymorphisms and breast cancer risk

Authors: Jie Wang, Qi He, Yu-guo Shao, Min Ji, Wei Bao

Published in: Tumor Biology | Issue 6/2013

Login to get access

Abstract

Many epidemiologic studies have investigated the association between vitamin D receptor (VDR) gene polymorphisms and breast cancer risk, but the results were inconsistent. We performed a meta-analysis of 31 studies on VDR polymorphisms, including FokI, BsmI, TaqI, and ApaI, and breast cancer risk published before May 2013. For FokI, the allele of f was found to be associated with increased risk of breast cancer compared with F (OR, 1.19; 95 % CI, 1.03–1.36). Patients with ff genotype were at significantly higher risk of breast cancer compared with those with FF genotype (OR, 1.95; 95 % CI, 1.66–2.29). In subgroup analysis by race, Fok1 polymorphism was significantly associated with breast cancer risk for Caucasian population (f vs. F: OR, 1.35; 95 % CI, 1.14–1.59; ff vs. FF: OR, 2.18; 95 % CI, 1.86–2.54; ff vs. FF + Ff: OR, 1.16; 95 % CI, 1.03–1.30). For ApaI, aa genotype was associated with increased breast cancer risk in Asian population based on four studies (aa vs. Aa + AA, OR, 1.49; 95 % CI, 1.12–1.98). No significant association was found between breast cancer risk and ApaI and TaqI polymorphism in different models and populations. Our updated meta-analysis showed that Fok1 polymorphism is associated with breast cancer risk both in general population and in Caucasian population. ApaI polymorphism might be associated with breast cancer risk in Asian population. Large well-designed epidemiological studies are necessary to clarify the risk identified in the current meta-analysis.
Literature
1.
Bauer SR, Hankinson SE, Bertone-Johnson ER, Ding EL. Plasma vitamin D levels, menopause, and risk of breast cancer: dose–response meta-analysis of prospective studies. Med (Baltimore). 2013;92:123–31.CrossRef
2.
Lopes N, Sousa B, Martins D, Gomes M, Vieira D, Veronese LA, et al. Alterations in vitamin D signaling and metabolic pathways in breast cancer progression: a study of VDR, cyp27b1, and cyp24a1 expression in benign and malignant breast lesions. BMC Cancer. 2010;10:483.PubMedCrossRef
3.
Tang C, Chen N, Wu M, Yuan H, Du Y. Fok1 polymorphism of vitamin D receptor gene contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat. 2009;117:391–9.PubMedCrossRef
4.
Raimondi S, Johansson H, Maisonneuve P, Gandini S. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis. 2009;30:1170–80.PubMedCrossRef
5.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRef
6.
Ruggiero M, Pacini S, Aterini S, Fallai C, Ruggiero C, Pacini P. Vitamin D receptor gene polymorphism is associated with metastatic breast cancer. Oncol Res. 1998;10:43–6.PubMed
7.
Curran JE, Vaughan T, Lea RA, Weinstein SR, Morrison NA, Griffiths LR. Association of a vitamin D receptor polymorphism with sporadic breast cancer development. Int J Cancer. 1999;83:723–6.PubMedCrossRef
8.
Dunning AM, McBride S, Gregory J, Durocher F, Foster NA, Healey CS, et al. No association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancer. Carcinogenesis. 1999;20:2131–5.PubMedCrossRef
9.
Lundin AC, Soderkvist P, Eriksson B, Bergman-Jungestrom M, Wingren S. Association of breast cancer progression with a vitamin D receptor gene polymorphism. South-east Sweden breast cancer group. Cancer Res. 1999;59:2332–4.PubMed
10.
Ingles SA, Garcia DG, Wang W, Nieters A, Henderson BE, Kolonel LN, et al. Vitamin D receptor genotype and breast cancer in Latinas (US). Cancer Causes Control. 2000;11:25–30.PubMedCrossRef
11.
Bretherton-Watt D, Given-Wilson R, Mansi JL, Thomas V, Carter N, Colston KW. Vitamin D receptor gene polymorphisms are associated with breast cancer risk in a UK Caucasian population. Br J Cancer. 2001;85:171–5.PubMedCrossRef
12.
Jing C, Kunwei S, Zhenzou S, Feng J, Fumin S. Relationship of vitamin D receptor polymorphism with breast cancer. Chin J Med Genet. 2001;18:286–8.
13.
Hou MF, Tien YC, Lin GT, Chen CJ, Liu CS, Lin SY, et al. Association of vitamin D receptor gene polymorphism with sporadic breast cancer in Taiwanese patients. Breast Cancer Res Treat. 2002;74:1–7.PubMedCrossRef
14.
Buyru N, Tezol A, Yosunkaya-Fenerci E, Dalay N. Vitamin D receptor gene polymorphisms in breast cancer. Exp Mol Med. 2003;35:550–5.PubMedCrossRef
15.
Guy M, Lowe LC, Bretherton-Watt D, Mansi JL, Peckitt C, Bliss J, et al. Vitamin D receptor gene polymorphisms and breast cancer risk. Clin Cancer Res. 2004;10:5472–81.PubMedCrossRef
16.
Hefler LA, Tempfer CB, Grimm C, Lebrecht A, Ulbrich E, Heinze G, et al. Estrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women. Cancer. 2004;101:264–9.PubMedCrossRef
17.
Sillanpaa P, Hirvonen A, Kataja V, Eskelinen M, Kosma VM, Uusitupa M, et al. Vitamin D receptor gene polymorphism as an important modifier of positive family history related breast cancer risk. Pharmacogenetics. 2004;14:239–45.PubMedCrossRef
18.
Chen WY, Bertone-Johnson ER, Hunter DJ, Willett WC, Hankinson SE. Associations between polymorphisms in the vitamin D receptor and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2005;14:2335–9.PubMedCrossRef
19.
Lowe LC, Guy M, Mansi JL, Peckitt C, Bliss J, Wilson RG, et al. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype, and breast cancer risk in a UK Caucasian population. Eur J Cancer. 2005;41:1164–9.PubMedCrossRef
20.
VandeVord PJ, Wooley PH, Darga LL, Severson RK, Wu B, Nelson DA. Genetic determinants of bone mass do not relate with breast cancer risk in us white and African–American women. Breast Cancer Res Treat. 2006;100:103–7.PubMedCrossRef
21.
John EM, Schwartz GG, Koo J, Wang W, Ingles SA. Sun exposure, vitamin D receptor gene polymorphisms, and breast cancer risk in a multiethnic population. Am J Epidemiol. 2007;166:1409–19.PubMedCrossRef
22.
McCullough ML, Stevens VL, Diver WR, Feigelson HS, Rodriguez C, Bostick RM, et al. Vitamin D pathway gene polymorphisms, diet, and risk of postmenopausal breast cancer: a nested case–control study. Breast Cancer Res. 2007;9:R9.PubMedCrossRef
23.
Trabert B, Malone KE, Daling JR, Doody DR, Bernstein L, Ursin G, et al. Vitamin D receptor polymorphisms and breast cancer risk in a large population-based case–control study of Caucasian and African–American women. Breast Cancer Res. 2007;9:R84.PubMedCrossRef
24.
Abbas S, Nieters A, Linseisen J, Slanger T, Kropp S, Mutschelknauss EJ, et al. Vitamin D receptor gene polymorphisms and haplotypes and postmenopausal breast cancer risk. Breast Cancer Res. 2008;10:R31.PubMedCrossRef
25.
Sinotte M, Rousseau F, Ayotte P, Dewailly E, Diorio C, Giguere Y, et al. Vitamin D receptor polymorphisms (FOKI, BSMI) and breast cancer risk: association replication in two case–control studies within French–Canadian population. Endocr Relat Cancer. 2008;15:975–83.PubMedCrossRef
26.
Chakraborty A, Mishra AK, Soni A, Regina T, Mohil R, Bhatnagar D, et al. Vitamin D receptor gene polymorphism(s) and breast cancer risk in north Indians. Cancer Detect Prev. 2009;32:386–94.PubMedCrossRef
27.
McKay JD, McCullough ML, Ziegler RG, Kraft P, Saltzman BS, Riboli E, et al. Vitamin D receptor polymorphisms and breast cancer risk: results from the national cancer institute breast and prostate cancer cohort consortium. Cancer Epidemiol Biomarkers Prev. 2009;18:297–305.PubMedCrossRef
28.
Anderson LN, Cotterchio M, Cole DE, Knight JA. Vitamin D-related genetic variants, interactions with vitamin D exposure, and breast cancer risk among Caucasian women in Ontario. Cancer Epidemiol Biomarkers Prev. 2011;20:1708–17.PubMedCrossRef
29.
Dequan L, Haichao Z, Tianning Z, Yong Z, Zhuangqing Y, Ting Y. Association between the genetic polymorphisms of Vitamin D receptor and sporadic breast cancer risk in Yunnan women of Han nationality. J Kunming Med Univ. 2011;32:91–4.
30.
Dalessandri KM, Miike R, Wiencke JK, Farren G, Pugh TW, Manjeshwar S, et al. Vitamin D receptor polymorphisms and breast cancer risk in a high-incidence population: a pilot study. J Am Coll Surg. 2012;215:652–7.PubMedCrossRef
31.
Engel LS, Orlow I, Sima CS, Satagopan J, Mujumdar U, Roy P, et al. Vitamin D receptor gene haplotypes and polymorphisms and risk of breast cancer: a nested case–control study. Cancer Epidemiol Biomarkers Prev. 2012;21:1856–67.PubMedCrossRef
32.
Huang Y, Lu H, Bai Y, Chen Y, Zeng Y, Pan Y. Relationship between genotypes and haplotypes of vitamin D receptor gene and breast cancer risk. J Med Res. 2012;41:89–92.
33.
Rollison DE, Cole AL, Tung KH, Slattery ML, Baumgartner KB, Byers T, et al. Vitamin D intake, vitamin D receptor polymorphisms, and breast cancer risk among women living in the southwestern US. Breast Cancer Res Treat. 2012;132:683–91.PubMedCrossRef
34.
Fuhrman BJ, Freedman DM, Bhatti P, Doody MM, Fu YP, Chang SC, et al. Sunlight, polymorphisms of vitamin D-related genes, and risk of breast cancer. Anticancer Res. 2013;33:543–51.PubMed
35.
Mishra DK, Wu Y, Sarkissyan M, Sarkissyan S, Chen Z, Shang X, et al. Vitamin D receptor gene polymorphisms and prognosis of breast cancer among African–American and Hispanic women. PLoS One. 2013;8:e57967.PubMedCrossRef
36.
Shahbazi S, Alavi S, Majidzadeh AK, Ghaffarpour M, Soleimani A, Mahdian R. BSMI but not FOKI polymorphism of VDR gene is contributed in breast cancer. Med Oncol. 2013;30:393.PubMedCrossRef
37.
38.
39.
Carlberg C. Current understanding of the function of the nuclear vitamin D receptor in response to its natural and synthetic ligands. Recent Results Cancer Res. 2003;164:29–42.PubMedCrossRef
40.
Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. Gene. 2004;338:143–56.PubMedCrossRef
41.
Uitterlinden AG, Fang Y, van Meurs JB, van Leeuwen H, Pols HA. Vitamin D receptor gene polymorphisms in relation to vitamin D related disease states. J Steroid Biochem Mol Biol. 2004;89–90:187–93.PubMedCrossRef
42.
John EM, Schwartz GG, Dreon DM, Koo J. Vitamin D and breast cancer risk: The NHANES I epidemiologic follow-up study, 1971–1975 to 1992. National health and nutrition examination survey. Cancer Epidemiol Biomarkers Prev. 1999;8:399–406.PubMed
43.
Rossi M, McLaughlin JK, Lagiou P, Bosetti C, Talamini R, Lipworth L, et al. Vitamin D intake and breast cancer risk: a case–control study in Italy. Ann Oncol. 2009;20:374–8.PubMedCrossRef
44.
Abbas S, Linseisen J, Slanger T, Kropp S, Mutschelknauss EJ, Flesch-Janys D, et al. The gc2 allele of the vitamin D binding protein is associated with a decreased postmenopausal breast cancer risk, independent of the vitamin D status. Cancer Epidemiol Biomarkers Prev. 2008;17:1339–43.PubMedCrossRef
Metadata
Title
Associations between vitamin D receptor polymorphisms and breast cancer risk
Authors
Jie Wang
Qi He
Yu-guo Shao
Min Ji
Wei Bao
Publication date
01-12-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0967-9

Other articles of this Issue 6/2013

Tumor Biology 6/2013 Go to the issue

Research Article

Tropomyosin-4 correlates with higher SBR grades and tubular differentiation in infiltrating ductal breast carcinomas: an immunohistochemical and proteomics-based study

Research Article

Abnormal expression of insulin-like growth factor-I receptor in hepatoma tissue and its inhibition to promote apoptosis of tumor cells

Research Article

CYP1A1 exon7 polymorphism is associated with lung cancer risk among the female population and among smokers: a meta-analysis

Research Article

Nicotinamide N-methyltransferase overexpression is associated with Akt phosphorylation and indicates worse prognosis in patients with nasopharyngeal carcinoma

Research Article

Thrombomodulin mediates the progression of epithelial ovarian cancer cells

Research Article

Human papillomavirus is independent prognostic factor on outcome of oropharyngeal squamous cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits